© 2025 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Asia

Top Section

Top Section

India is on track for a record year of IPOs. Global tech giants continue to plough capital into a fast-growing consumer economy that is investing heavily in ensuring it’s a major player — along with the US and China — in an AI-first world
◆ Deal finds demand despite arrest of South Korea's president ◆ High single digit concession left for investors ◆ Leads added spread to calm concerns
South Korean policy lender kickstarts 2025 funding following a month of political chaos
More articles

More articles

More articles

  • Chinese electric vehicle manufacturer Li Auto has raised $750m from its debut convertible bond, pricing the deal at the investor-friendly end of the marketed range.
  • We Doctor Holdings, which operates Chinese healthcare platform WeDoctor, is seeking approval for a Hong Kong IPO.
  • China’s Fortune Auto Finance Co launched its first internationally rated auto loan ABS transaction this week, pricing the senior portion of the Rmb2.5bn ($381.5m) deal at a competitive spread.
  • Greater China issuers are eagerly turning to the international loan market again for funding, encouraged by low pricing and flush liquidity to refinance debt early and raise new money. But there are still many roadblocks, with banks cautious about predicting a quick recovery to pre-Covid levels. Pan Yue reports.
  • Investors put in a staggering $60bn of orders for an accelerated offering of Tencent Holdings’ stock on Wednesday, a deal that saw Dutch internet company Prosus taking home HK$114.17bn ($14.67bn) from a record-breaking overnight share sale. Jonathan Breen reports.
  • Hong Kong has now vaccinated half a million people, after rolling its vaccine out to all comers last month. There have been a few hiccups – the discovery of packaging defects caused a temporary halt to the AstraZeneca jab — but most people have now had the first of their required two shots.
shared comment list